Epworth Knowledge Services

                                                                                      COVID-19 UPDATES

Molnupiravir

• Interim analysis from Merck
• TGA grants provisional determination 

General Updates

• Updates to the Living Treatment Guideline, including Seven new treatment recommendations for pregnant and breastfeeding women. from the National COVID-19 Clinical Evidence Taskforce
• ATAGI statement about the need for additional doses of COVID-19 vaccines
• Adapting Physical Therapy Management of Patients With COVID-19 in the Acute Care Setting: A Clinical Perspective from Cardiopulmonary Physical Therapy Journal 
• Clinical Characteristics and Outcomes of Adults With a History of Heart Failure Hospitalized for COVID-19 from Circulation: Heart Failure
• COVID-19 Vaccines for Moderately to Severely Immunocompromised People from CDC
• Real-world data show that filters clean COVID-causing virus from air from Nature
• Melbourne-made COVID-19 treatment could future-proof Australia by WEHI
• ATAGI statement on the use of a 3rd primary dose of COVID-19 vaccine in individuals who are severely immunocompromised

Discussion

• Authors argue that the case for a 3rd dose for the general population is weak, stating “multiple studies have found sustained vaccine effectiveness against severe COVID-19 for most adults”. Side effects after a third dose are similar to those of a second dose, with “no unexpected patterns of adverse reactions”.
• In vaccinated patients, the highest risk of COVID-19 related death and hospital admission were observed for patients with Down’s syndrome, kidney transplantation, sickle cell disease, and several other conditions.